Evidence map›Paper›PMID 39034332›Full record

ArticleNPJ vaccines2024

A trivalent protein-based pan-Betacoronavirus vaccine elicits cross-neutralizing antibodies against a panel of coronavirus pseudoviruses.

Syamala Rani Thimmiraju, Rakesh Adhikari, JeAnna R Redd, Maria Jose Villar, Jungsoon Lee, Zhuyun Liu, Yi-Lin Chen, Suman Sharma, Amandeep Kaur, Nestor L Uzcategui and 8 more

Abstract read
In one paragraph

Article in NPJ vaccines, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors.

Syamala Rani ThimmirajuTexas Children's Hospital Center for Vaccine Development, Houston, TX, 77030, USA.
Rakesh AdhikariTexas Children's Hospital Center for Vaccine Development, Houston, TX, 77030, USA.
JeAnna R ReddTexas Children's Hospital Center for Vaccine Development, Houston, TX, 77030, USA.
Maria Jose VillarTexas Children's Hospital Center for Vaccine Development, Houston, TX, 77030, USA.
Jungsoon LeeTexas Children's Hospital Center for Vaccine Development, Houston, TX, 77030, USA.
Zhuyun LiuTexas Children's Hospital Center for Vaccine Development, Houston, TX, 77030, USA.
Yi-Lin ChenTexas Children's Hospital Center for Vaccine Development, Houston, TX, 77030, USA.
Suman SharmaDepartment of Molecular Virology and Microbiology, Baylor College of Medicine, Houston, TX, 77030, USA.
Amandeep KaurTexas Children's Hospital Center for Vaccine Development, Houston, TX, 77030, USA.
Nestor L UzcateguiTexas Children's Hospital Center for Vaccine Development, Houston, TX, 77030, USA.
Shannon E RoncaTexas Children's Hospital Center for Vaccine Development, Houston, TX, 77030, USA.
Wen-Hsiang ChenTexas Children's Hospital Center for Vaccine Development, Houston, TX, 77030, USA.ORCID http://orcid.org/0000-0002-0542-1598
Jason T KimataDepartment of Molecular Virology and Microbiology, Baylor College of Medicine, Houston, TX, 77030, USA.ORCID http://orcid.org/0000-0002-0504-0090
Bin ZhanTexas Children's Hospital Center for Vaccine Development, Houston, TX, 77030, USA.
Ulrich StrychTexas Children's Hospital Center for Vaccine Development, Houston, TX, 77030, USA.ORCID http://orcid.org/0000-0001-9455-7683
Maria Elena BottazziTexas Children's Hospital Center for Vaccine Development, Houston, TX, 77030, USA.ORCID http://orcid.org/0000-0002-8429-0476
Peter J HotezTexas Children's Hospital Center for Vaccine Development, Houston, TX, 77030, USA.
Jeroen PolletTexas Children's Hospital Center for Vaccine Development, Houston, TX, 77030, USA. Jeroen.pollet@bcm.edu.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The development of broad-spectrum coronavirus vaccines is essential to prepare for future respiratory virus pandemics. We demonstrated broad neutralization by a trivalent subunit vaccine, formulating the receptor-binding domains of SARS-CoV, MERS-CoV, and SARS-CoV-2 XBB.1.5 with Alum and CpG55.2. Vaccinated mice produced cross-neutralizing antibodies against all three human Betacoronaviruses and others currently exclusive to bats, indicating the epitope preservation of the individual antigens during co-formulation and the potential for epitope broadening.

Identifiers

PMID39034332
PMCPMC11271464

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.